{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:50:16Z","timestamp":1790733016509,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T00:00:00Z","timestamp":1734134400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck & Co Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003042","name":"Else Kroner-Fresenius Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.annonc.2024.12.009","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T03:00:08Z","timestamp":1734490808000},"page":"393-402","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Correlation between progression-free and overall survival in patients with Hodgkin lymphoma: a comprehensive analysis of individual patient data from randomized German Hodgkin Study Group (GHSG) trials"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9662-9900","authenticated-orcid":false,"given":"P.J.","family":"Br\u00f6ckelmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gillessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.A.","family":"Eichenauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Borchmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.S.","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7035-1784","authenticated-orcid":false,"given":"K.","family":"Behringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Momotow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3481-7997","authenticated-orcid":false,"given":"J.","family":"Ferdinandus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"B\u00f6ll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Kobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.-T.","family":"Eich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Baues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Klapper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Engert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Borchmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1410-4487","authenticated-orcid":false,"given":"B.","family":"von Tresckow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2024.12.009_bib1","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.2016.70.9410","article-title":"Long-term follow-up of contemporary treatment in early-stage Hodgkin lymphoma: updated analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 trials","volume":"35","author":"Sasse","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.12.009_bib2","doi-asserted-by":"crossref","first-page":"e398","DOI":"10.1016\/S2352-3026(21)00101-0","article-title":"PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial","volume":"8","author":"Kreissl","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.annonc.2024.12.009_bib3","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin\u2019s lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2024.12.009_bib4","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41375-021-01442-8","article-title":"Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis","volume":"36","author":"Brockelmann","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.annonc.2024.12.009_bib5","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/bjh.17891","article-title":"Unfolding the potential of anti-programmed cell death protein 1 blockade in Hodgkin lymphoma - combination and personalisation?","volume":"196","author":"Brockelmann","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.annonc.2024.12.009_bib6","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/annonc\/mdz004","article-title":"Outcomes of patients with the third or higher relapsed classical Hodgkin lymphoma: results from the German Hodgkin Study Group","volume":"30","author":"Brockelmann","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2024.12.009_bib7","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1080\/10428194.2018.1540781","article-title":"Survivors\u2019 perspectives on risks and benefits of Hodgkin lymphoma treatment: results of a survey by the German Hodgkin Study Group","volume":"60","author":"Kreissl","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.annonc.2024.12.009_bib8","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/bjh.15566","article-title":"Patient and physician preferences for first-line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom","volume":"184","author":"Brockelmann","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.annonc.2024.12.009_bib9","unstructured":"Guideline on the clinical evaluation of anticancer medicinal products - Revision 6. European Medicines Agency; 2024. Available at https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-evaluation-anticancer-medicinal-products-revision-6_en.pdf. Accessed 13 January 2025."},{"key":"10.1016\/j.annonc.2024.12.009_bib10","series-title":"Development and approval process\u2014Drugs","year":"2022"},{"key":"10.1016\/j.annonc.2024.12.009_bib11","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1200\/JCO.23.00225","article-title":"Irreconcilable differences: the divorce between response rates, progression-free survival, and overall survival","volume":"41","author":"Merino","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.12.009_bib12","doi-asserted-by":"crossref","first-page":"e462","DOI":"10.1016\/S2352-3026(18)30140-6","article-title":"Intensive treatment strategies in advanced-stage Hodgkin\u2019s lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials","volume":"5","author":"von Tresckow","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.annonc.2024.12.009_bib13","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","article-title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin\u2019s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial","volume":"379","author":"Engert","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2024.12.009_bib14","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/S0140-6736(14)61469-0","article-title":"Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin\u2019s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial","volume":"385","author":"Behringer","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2024.12.009_bib15","doi-asserted-by":"crossref","first-page":"e278","DOI":"10.1016\/S2352-3026(21)00029-6","article-title":"Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14)","volume":"8","author":"Gillessen","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.annonc.2024.12.009_bib16","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1213\/ANE.0000000000002864","article-title":"Correlation coefficients: appropriate use and interpretation","volume":"126","author":"Schober","year":"2018","journal-title":"Anesth Analg"},{"key":"10.1016\/j.annonc.2024.12.009_bib17","series-title":"Statistics at Square One","article-title":"Chapter 11: Correlation and regression","author":"Swinscow","year":"1997"},{"key":"10.1016\/j.annonc.2024.12.009_bib18","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1037\/0033-2909.112.1.155","article-title":"A\u00a0power primer","volume":"112","author":"Cohen","year":"1992","journal-title":"Psychol Bull"},{"key":"10.1016\/j.annonc.2024.12.009_bib19","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A\u00a0prognostic score for advanced Hodgkin\u2019s disease. International Prognostic Factors Project on advanced Hodgkin\u2019s disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2024.12.009_bib20","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1080\/01621459.1989.10478873","article-title":"Regression analysis of multivariate incomplete failure time data by modeling marginal distributions","volume":"84","author":"Wei","year":"1989","journal-title":"J\u00a0Am Stat Assoc"},{"key":"10.1016\/j.annonc.2024.12.009_bib21","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1198\/000313004X5419","article-title":"A\u00a0review of software packages for analyzing correlated survival data","volume":"58","author":"Kelly","year":"2004","journal-title":"Am Stat"},{"key":"10.1016\/j.annonc.2024.12.009_bib22","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/sim.8001","article-title":"Quantifying the association between progression-free survival and overall survival in oncology trials using Kendall\u2019s","volume":"38","author":"Weber","year":"2019","journal-title":"Stat Med"},{"key":"10.1016\/j.annonc.2024.12.009_bib23","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1080\/01621459.1993.10476372","article-title":"Statistical-inference procedures for bivariate Archimedean copulas","volume":"88","author":"Genest","year":"1993","journal-title":"J\u00a0Am Stat Assoc"},{"key":"10.1016\/j.annonc.2024.12.009_bib24","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1017\/S0266462318000338","article-title":"Challenges and methodologies in using progression free survival as a surrogate for overall survival in oncology","volume":"34","author":"Hernandez-Villafuerte","year":"2018","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.annonc.2024.12.009_bib25","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/s41416-020-0805-y","article-title":"Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review","volume":"122","author":"Belin","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.annonc.2024.12.009_bib26","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1471-2288-12-27","volume":"12","author":"Lassere","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.annonc.2024.12.009_bib27","article-title":"Validity of surrogate endpoints in oncology","year":"2011","journal-title":"IQWiG Reports. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG)"},{"key":"10.1016\/j.annonc.2024.12.009_bib28","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12955-018-0920-0","article-title":"Understanding the quality of life (QOL) issues in survivors of cancer: towards the development of an EORTC QOL cancer survivorship questionnaire","volume":"16","author":"van Leeuwen","year":"2018","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.annonc.2024.12.009_bib29","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1182\/blood-2023-188720","article-title":"Comprehensive analysis of treatment related morbidity and progression-free survival in the GHSG phase III HD21 trial","volume":"142","author":"Borchmann","year":"2023","journal-title":"Blood"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753424049883?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753424049883?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T05:13:47Z","timestamp":1762319627000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753424049883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0923753424049883"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2024.12.009","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Correlation between progression-free and overall survival in patients with Hodgkin lymphoma: a comprehensive analysis of individual patient data from randomized German Hodgkin Study Group (GHSG) trials","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2024.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}